All-time high financial and operational results were achieved, with net revenue up 12% and adjusted EBITDA margin rising to 22.2%. Major investments in robotic surgery and CAR-T cell therapy drove innovation, while debt maturity was extended and cost reduced.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.